Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019

Abstract

For all approved therapeutic agents, the time frame has been extended to cover the almost 39 years from the first of January 1981 to the 30th of September 2019 for all diseases worldwide and from ∼1946 (earliest so far identified) to the 30th of September 2019 for all approved antitumor drugs worldwide. As in earlier reviews, only the first approval of any drug is counted, irrespective of how many "biosimilars" or added approvals were subsequently identified. As in the 2012 and 2016 reviews, we have continued to utilize our secondary subdivision of a "natural product mimic", or "NM", to join the original primary divisions, and the designation "natural product botanical", or "NB", to cover those botanical "defined mixtures" now recognized as drug entities by the FDA (and similar organizations). From the data presented in this review, the utilization of natural products and/ or synthetic variations using their novel structures, in order to discover and develop the final drug entity, is still alive and well. For example, in the area of cancer, over the time frame from 1946 to 1980, of the 75 small molecules, 40, or 53.3%, are N or ND. In the 1981 to date time frame the equivalent figures for the N* compounds of the 185 small molecules are 62, or 33.5%, though to these can be added the 58 S* and S*/NMs, bringing the figure to 64.9%. In other areas, the influence of natural product structures is quite marked with, as expected from prior information, the anti-infective area being dependent on natural products and their structures, though as can be seen in the review there are still disease areas (shown in Table 2) for which there are no drugs derived from natural products. Although combinatorial chemistry techniques have succeeded as methods of optimizing structures and have been used very successfully in the optimization of many recently approved agents, we are still able to identify only two de novo combinatorial compounds (one of which is a little speculative) approved as drugs in this 39-year time frame, though there is also one drug that was developed using the "fragment-binding methodology" and approved in 2012. We have also added a discussion of candidate drug entities currently in clinical trials as "warheads" and some very interesting preliminary reports on sources of novel antibiotics from Nature due to the absolute requirement for new agents to combat plasmid-borne resistance genes now in the general populace. We continue to draw the attention of readers to the recognition that a significant number of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the "host from whence it was isolated"; thus we consider that this area of natural product research should be expanded significantly.

High-performance Countercurrent Chromatography to Access Rhodiola rosea Influenza Virus Inhibiting Constituents

“…The continuing impact of natural products in modern medicine [40] emphasizes the importance of scrutinizing the phytochemical universe of plant secondary metabolites. Getting access to isolates forms the basis for quality control and standardization proce-▶ Table 3 Stepwise gradient elution program of the developed HPCCC method.…”

Promising Medicinal Plants with Diuretic Potential Used in Brazil: State of the Art, Challenges, and Prospects

“…Flavonoids, for instance, have been proven to prevent or attenuate cardiac and renal injuries associated with hypertension by interfering with the multiple signaling pathways [46]. One such flavonoid of interest is (−)-epicatechin [1], which is abundant in several plants and food products, including cocoa, green tea, juice, and wine. According to the literature, this compound can be beneficial for human health, including in cardiovascular disorders [47].…”

Ranking microbial metabolomic and genomic links in the NPLinker framework using complementary scoring functions

“…Microbial specialised metabolism, i.e. microbial production of metabolites not strictly needed for the survival of the organism, has been a rich source of metabolites for a variety of biomedical applications (Newman and Cragg, 2020). Recent advances in genomic analysis Hannigan et al, 2019;Cimermancic et al, 2014) indicate that microorganisms harbour considerable untapped metabolomic potential (Baltz, 2017).…”